Histone Deacetylase Inhibitors: A Prospect in Drug Discovery

Turkish Journal of Pharmaceutical Sciences

article

Rakesh YADAV¹  Pooja MISHRA¹  Divya YADAV¹ 

[1] Banasthali University, Faculty of Pharmacy, Department of Pharmacy

关键词: Histone deacetylase inhibitors;    apoptosis;    multitherapeutic approach;    cancer;   

DOI  :  10.4274/tjps.75047

来源: Galenos Yayinevi

【 摘 要 】

Cancer is a provocative issue across the globe and treatment of uncontrolled cell growth follows a deep investigation in the field of drug discovery. Therefore, there is a crucial requirement for discovering an ingenious medicinally active agent that can amend idle drug targets. Increasing pragmatic evidence implies that histone deacetylases (HDACs) are trapped during cancer progression, which increases deacetylation and triggers changes in malignancy. They provide a ground-breaking scaffold and an attainable key for investigating chemical entity pertinent to HDAC biology as a therapeutic target in the drug discovery context. Due to gene expression, an impending requirement to prudently transfer cytotoxicity to cancerous cells, HDAC inhibitors may be developed as anticancer agents. The present review focuses on the basics of HDAC enzymes, their inhibitors, and therapeutic outcomes.

【 授权许可】

Unknown